Perspective Therapeutics
Perspective Therapeutics is a clinical-stage radiopharmaceutical company dedicated to developing innovative, image-guided, targeted alpha-particle therapies for cancer treatment. The company's proprietary technology utilizes Pb-212 to deliver powerful radiation directly to cancer cells, with a theranostic platform that incorporates imaging diagnostics for personalized treatment. Their focus is on advancing cancer treatments using targeted alpha-radiation, leveraging high-affinity targeting peptides, and expanding manufacturing capabilities. They have a strong pipeline of programs targeting melanoma, neuroendocrine tumors, and solid tumors, with ongoing clinical trials and collaborations with leading medical institutions.
Industries
Nr. of Employees
medium (51-250)
Perspective Therapeutics
Products
MC1R-targeted theranostic radiopharmaceutical for melanoma (imaging + alpha therapy)
A peptide-based theranostic pair using a diagnostic lead isotope for imaging to select MC1R-expressing melanoma patients and a therapeutic lead isotope for alpha-particle therapy.
SSTR2-targeted theranostic radiopharmaceutical for neuroendocrine tumors
Peptide-based diagnostic and therapeutic lead-isotope pair designed to image and treat SSTR2-expressing neuroendocrine tumors in an image-guided alpha-particle therapy program.
FAP-α-targeted pan-cancer radiopharmaceutical (PSV359)
A therapeutic program targeting fibroblast activation protein-alpha (FAP-α) expressed in tumor stroma across multiple solid tumor types, evaluated as an image-guided alpha therapy.
PSMA-targeted prostate theranostic program
An imaging and therapy program aimed at prostate-specific membrane antigen (PSMA)-expressing prostate cancer using matched imaging and alpha-therapy lead isotopes.
Pre-targeting radioimmunotherapy platform (host–guest chemistry)
Two-step platform that converts antibodies or protein fragments into pretargeting carriers (bearing a host chemistry moiety) followed by administration of a small radioligand that binds the host moiety to concentrate radiation at tumor sites with reduced off-target exposure.
MC1R-targeted theranostic radiopharmaceutical for melanoma (imaging + alpha therapy)
A peptide-based theranostic pair using a diagnostic lead isotope for imaging to select MC1R-expressing melanoma patients and a therapeutic lead isotope for alpha-particle therapy.
SSTR2-targeted theranostic radiopharmaceutical for neuroendocrine tumors
Peptide-based diagnostic and therapeutic lead-isotope pair designed to image and treat SSTR2-expressing neuroendocrine tumors in an image-guided alpha-particle therapy program.
FAP-α-targeted pan-cancer radiopharmaceutical (PSV359)
A therapeutic program targeting fibroblast activation protein-alpha (FAP-α) expressed in tumor stroma across multiple solid tumor types, evaluated as an image-guided alpha therapy.
PSMA-targeted prostate theranostic program
An imaging and therapy program aimed at prostate-specific membrane antigen (PSMA)-expressing prostate cancer using matched imaging and alpha-therapy lead isotopes.
Pre-targeting radioimmunotherapy platform (host–guest chemistry)
Two-step platform that converts antibodies or protein fragments into pretargeting carriers (bearing a host chemistry moiety) followed by administration of a small radioligand that binds the host moiety to concentrate radiation at tumor sites with reduced off-target exposure.
Services
Expanded access (compassionate use) process
Review and potential provision of investigational radiopharmaceuticals to individual patients outside clinical trials when criteria are met; includes request intake, eligibility review, and compliance requirements.
Clinical trial partnerships and site collaborations
Sponsorship and operational support for early-phase imaging and therapeutic clinical trials, including multi-site recruitment and imaging cohorts.
Expanded access (compassionate use) process
Review and potential provision of investigational radiopharmaceuticals to individual patients outside clinical trials when criteria are met; includes request intake, eligibility review, and compliance requirements.
Clinical trial partnerships and site collaborations
Sponsorship and operational support for early-phase imaging and therapeutic clinical trials, including multi-site recruitment and imaging cohorts.
Expertise Areas
- Targeted alpha-particle radiopharmaceuticals
- Theranostics and companion diagnostics
- Radiochemistry and chelator development
- Isotope production and generator technologies
Key Technologies
- Lead-212 alpha-emitting therapeutic isotopes
- Lead-203 SPECT imaging isotopes
- Lead-specific chelator chemistry
- Tumor-targeting peptide conjugates